Ionis Pharmaceuticals, Inc. (IONS)

41,59 -0,25 (-0,60%) Börsenschluss: 04:00PM EDT

Ionis Pharmaceuticals, Inc.

2855 Gazelle Court
Carlsbad, CA 92010
United States
760 931 9200
https://www.ionispharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 927

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Brett P. Monia Ph.D.	Founder, CEO & Director	2,38M	2,38M	1961
Ms. Elizabeth L. Hougen M.A., M.B.A., M.S.	Executive VP of Finance & CFO	1,14M	2,28M	1962
Ms. B. Lynne Parshall Esq., J.D.	Senior Strategic Advisor & Director	90k	5,94M	1954
Dr. Richard S. Geary Ph.D.	Executive VP & Chief Development Officer	1,01M	1,05M	1958
Mr. Darren Gonzales	Chief Accounting Officer & Senior VP	N/A	N/A	N/A
Dr. C. Frank Bennett BSc, Ph.D.	Executive VP & Chief Scientific Officer	651,64k	1,37M	1957
Mr. D. Wade Walke Ph.D.	Senior Vice President of Investor Relations	N/A	N/A	N/A
Mr. Patrick R. O'Neil Esq.	Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary	815,69k	N/A	1974
Ms. Hayley Soffer	Vice President of Corporate Communications	N/A	N/A	N/A
Ms. Shannon Devers	Senior Vice President of Human Resources	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Corporate Governance

Ionis Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. April 2024, lautet 3. Die grundlegenden Scores sind Audit: 3, Vorstand: 3, Shareholderrechte: 5, Kompensation: 4.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.